Jefferies Financial Group started coverage on shares of Vicore Pharma (NASDAQ:VCRE – Free Report) in a research note published on Friday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $25.00 price target on the stock.
Vicore Pharma Price Performance
NASDAQ:VCRE opened at $9.00 on Friday. Vicore Pharma has a fifty-two week low of $7.88 and a fifty-two week high of $17.80.
Vicore Pharma Company Profile
Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.
Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.
Further Reading
- Five stocks we like better than Vicore Pharma
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Vicore Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicore Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
